Conatus Pharmaceuticals Inc (CNAT) Expected to Post Quarterly Sales of $8.51 Million

Wall Street analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to report sales of $8.51 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The highest sales estimate is $10.00 million and the lowest is $6.13 million. Conatus Pharmaceuticals reported sales of $8.80 million in the same quarter last year, which indicates a negative year-over-year growth rate of 3.3%. The firm is expected to report its next earnings results on Wednesday, March 6th.

On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $34.81 million for the current fiscal year, with estimates ranging from $32.30 million to $36.18 million. For the next year, analysts anticipate that the firm will report sales of $46.87 million, with estimates ranging from $25.32 million to $80.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.15). The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $9.70 million. Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%.

Several analysts have recently commented on CNAT shares. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 1st. Finally, HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday, November 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Conatus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $11.80.

A number of hedge funds and other institutional investors have recently bought and sold shares of CNAT. Artal Group S.A. purchased a new stake in Conatus Pharmaceuticals during the third quarter worth about $2,900,000. BlackRock Inc. increased its holdings in Conatus Pharmaceuticals by 13.4% during the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock worth $9,419,000 after buying an additional 191,287 shares during the last quarter. Alambic Investment Management L.P. increased its holdings in Conatus Pharmaceuticals by 207.0% during the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 178,461 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $547,000. Finally, LMR Partners LLP purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $311,000. Institutional investors and hedge funds own 35.09% of the company’s stock.

Shares of CNAT stock traded down $0.17 on Thursday, hitting $4.48. The stock had a trading volume of 281,958 shares, compared to its average volume of 643,661. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. Conatus Pharmaceuticals has a 12-month low of $3.22 and a 12-month high of $7.95.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Read More: Correction

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit